1. How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? 
Vincenzo Mirone 
European Urology Supplements 
Volume 6, Issue 6, Pages (March 2007)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
The change in American Urological Association (AUA) Symptom Index score for minimally invasive therapies: results of an AUA meta-analysis [1].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
Secondary procedures required after minimally invasive therapies versus transurethral resection of the prostate and sham therapies: results of an American Urological Association meta-analysis [1].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
The incidence of common progression events at year 4 in the Medical Therapy of Prostatic Symptoms study [7].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

5. Fig. 4
An indirect across-study comparison of symptom improvement following treatment with α-blockers, finasteride, and dutasteride [1,7,9–11].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

6. Fig. 5
An indirect across-study comparison of long-term change in prostate volume following treatment with α-blockers, finasteride, and dutasteride [7,9–11].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions